Ring, Massachusetts Institute of Technology, Cambridge, and Jayakesh K from the Department of Civil Engineering, School of Engineering, Amrita Vishwa Vidyapeetham, Coimbatore, for their important and constructive recommendations through the improvement of this critique short article. We also thank the anonymous reviewers for critically reading the manuscript and suggesting substantial improvements. Conflicts of Interest: The authors declare no conflict of interest.Agriculture 2021, 11,12 of
biomedicinesArticleTyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical VentilationI-Hsien Lee 1 , Ching-Yao Yang 2, , Jin-Yuan Shihand Chong-Jen YuDepartment of Emergency and Fenbutatin oxide Protocol critical Care Medicine, Fu-Jen Sordarin medchemexpress Catholic University Hospital, New Taipei City 24308, Taiwan; [email protected] Division of Thoracic Medicine, Division of Internal Medicine, National Taiwan University Hospital, Taipei 10225, Taiwan; [email protected] (J.-Y.S.); [email protected] (C.-J.Y.) Correspondence: [email protected]: Lee, I.-H.; Yang, C.-Y.; Shih, J.-Y.; Yu, C.-J. Tyrosine Kinase Inhibitors Enhanced Survival of Critically Ill EGFR-Mutant Lung Cancer Sufferers Undergoing Mechanical Ventilation. Biomedicines 2021, 9, 1416. https://doi.org/ 10.3390/biomedicines9101416 Academic Editors: Massimo Moro and Luca Falzone Received: 11 September 2021 Accepted: 5 October 2021 Published: 8 OctoberAbstract: Background: Respiratory failure requiring mechanical ventilation would be the major reason for lung cancer individuals becoming admitted to the intensive care unit (ICU). Though molecular targeted therapies, especially epidermal development aspect receptor (EGFR)-tyrosine kinase inhibitors (TKIs), have largely enhanced the survival of oncogene-driven lung cancer sufferers, few research have focused on the functionality of TKI in such settings. Materials and Approaches: This was a retrospective cohort study enrolling non-small cell lung cancer (NSCLC) patients who harbored sensitizing EGFR mutation and had received EGFR-TKIs as first-line cancer therapy in the ICU with mechanical ventilator use. The primary outcome was the 28-day ICU survival rate, and secondary outcomes had been the price of effective weaning in the ventilator and general survival. Final results: A total of 35 sufferers were integrated. The 28-day ICU survival price was 77 , as well as the median all round survival was 67 days. Multivariate logistic regression revealed that shock status was associated with a reduced 28-day ICU survival price independently (odds ratio (OR) 0.017, 95 confidence interval (CI), 0.000.629, p = 0.027), and that L858R mutation (L858R compared with exon 19 deletion, OR, 0.014, 95 CI 0.000.450, p = 0.016) and comorbidities of diabetes mellitus (DM) (OR, 0.032, 95 CI, 0.000.416, p = 0.014)) have been independently predictive of weaning failure. The prosperous weaning price was 43 , along with the median of ventilator-dependent duration was 22 days (IQR, 129). Conclusions: For EGFR mutant lung cancer individuals struggling with respiratory failure and undergoing mechanical ventilation, TKI may possibly nonetheless be beneficial, especially in those with EGFR del19 mutation or with out shock and DM comorbidity. Keyword phrases: EGFR; lung cancer; critical care; mechanical ventilation; tyrosine kinase inhibitorPublisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.1. Introduction Lung cancer patients account for 8 of all intensive care unit (ICU) ad.
